ARIPIPRAZOLE

Methods
  • Efficacy was rated by using standard CGI, SF-12® and SIWM-PsySo® instruments for severity of disease, physical and mental health outcomes and psychosocial state, respectively.
  • Safety was evaluated according to the reports of adverse events.
  • Mean total daily dose of aripiprazole increased from 15.4 mg at the visit after 1 month to 17.6 mg at the visits after 6 to 12 months, the most frequently administered maintenance dose being 15 mg.
Results
  • Within the observation period significant improvements of CGI, SF-12® and SIWM-PsySo® scores over time versus baseline values were observed (p<0.001) when starting with or switching to aripiprazole.
  • Physicians observed improvements in 80.7% of the patients at endpoint; in 62% of the patients the disease state was considered “much” or “very much” improved.
  • Aripiprazole was overall well tolerated; 19.9% of patients discontinued treatment after 12 months.
  • Adverse effects in general were moderate to mild and corresponded to the known tolerability profile of aripiprazole.
  • Psychotic side effects reported were probably due to a recurrence of the underlying schizophrenic disorde

No comments:

Post a Comment